Roche Unveils AXELIOS 1 Sequencing Platform in Asia

Roche Diagnostics Korea hosted the 2026 AXELIOS Days event in Seoul to introduce the platform to Asia-Pacific researchers and laboratory experts.

Updated on Nov. 16, 2026 in Biotech

Isometric editorial illustration of a matte graphite sequencing instrument on a pale lab bench beside a row of sample tubes.
Roche Diagnostics Korea hosted its 2026 AXELIOS Days event in Seoul on November 12-13 to introduce the AXELIOS 1 sequencing platform to Asia-Pacific researchers. AI Illustration. Upload story photo >

Roche Diagnostics Korea held the 2026 AXELIOS Days event at The Shilla Seoul on November 12-13. The event introduced the AXELIOS 1 platform, which was globally launched in June 2026, to researchers and laboratory experts across the Asia-Pacific region.

Why it matters

The platform uses Roche Diagnostics' Scalable Base Sequencing technology and can confirm whole-genome analysis results on the same day. Its introduction in Asia-Pacific extends the platform's reach to research markets beyond its original global launch.

The platform converts DNA into synthetic molecules about 50 times longer than the original, a figure reported by the manufacturer rather than independently verified. Independent performance benchmarks and pricing have not been disclosed in the available information.

The players

Roche Diagnostics Korea

The South Korean arm of Swiss healthcare company Roche, which organizes diagnostic and laboratory product events in the region.

Macrogen

A South Korean genomics company that provides sequencing and genetic analysis services to researchers and clinics.

The details

AXELIOS 1 combines Roche's SBX technology with high-speed processing to analyze genetic information. Participants at the November event included Macrogen, the Garvan Institute, the Hartwig Medical Foundation, and researchers from the University of Tokyo, with attendees from South Korea, Japan, Singapore, Thailand, and Taiwan.

Timeline

  1. June 2026: AXELIOS 1 is globally launched.

  2. November 12-13, 2026: The 2026 AXELIOS Days event is held at The Shilla Seoul.

  3. November 16, 2026: Roche Diagnostics Korea announces the event.

The Tech Race

AXELIOS 1 is built on Roche's Scalable Base Sequencing technology and enters a competitive sequencing market dominated by established rivals. Its Asia-Pacific introduction positions Roche to contest genomics research spending in the region.

Researchers and clinical laboratories evaluating sequencing platforms may now consider AXELIOS 1 as an option for whole-genome analysis. The source does not state availability, pricing, or adoption timelines for individual users or institutions.

The takeaway

Faster same-day whole-genome results could shorten the time between sequencing and clinical or research decisions. Laboratories assessing new sequencing tools should weigh reported performance claims against independent validation as it becomes available.

Further reading

Explore more Biotech developments shaping genomic research worldwide.

Source note: This article includes information reported by 조선일보.